Abstract: The present invention relates to diphenylamino ketone derivatives, pharmaceutical compositions and methods of use thereof.

Abstract: Phenylamino benzhydroxamic acid derivatives of the formula where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as psoriasis and restenosis.

Abstract: The present invention relates to N-methyl-substituted benzamidazole derivatives of formula (I): as defined in the specification; pharmaceutical compositions and methods of use thereof.

Abstract: This invention provides substituted Phenyl-(2-[1,3,4]thiadiazol-2-yl-phenyl)-amine and (2-[1,3,4]Oxadiazol-2-yl-phenyl)phenyl-amine compounds which act as inhibitors of MAPK/ERK Kinase (“MEK”) enzymes and pharmaceutical compositions and methods for their use in immunomodulation and in the treatment and alleviation of inflammation, and proliferative diseases such as cancer and restenosis.

Abstract: This invention relates to a packet scheduler and method therefor and in particular a scheduler for a Code Division Multiple Access cellular mobile communication system. In packet base systems it is important to schedule transmissions of packets carefully in order to maximize the capacity of the system. The scheduler has a selection unit (233) for selecting a candidate set of packets. The candidate set is fed to a processor (235) for calculating transmit powers required by remote terminals to transmit the packets based on the candidate set. The calculated transmit powers are fed to a controller (237) for modifying the candidate set in response to the calculated transmit powers and the modified set is fed to a scheduler unit (239) for scheduling the packets of the candidate set for transmission. The scheduler is in particular appropriate for third generation mobile communication systems.

Abstract: The invention provides compounds of formula (II), wherein Ar, R3, R4, R5, R6, R7, R8 and W have the meanings given in the description. They are selective MEK inhibitors.

Abstract: The invention provides compounds having formula (I), wherein W is OH, or derivatives of the carboxylic acid, and Q is a heterocyclo-condensed ortho-phenylene residue. These compounds are useful as MEK inhibitors, particularly in the treatment of proliferative diseases such as cancer.

Abstract: A flexible component-based software system is developed by generating a UML model (3) in a specification phase (4). Components are generated in an implementation phase (4). The UML model (3) is transformed to a meta model. A runtime architecture service (RAS, 10) dynamically assembles a system in runtime according to the meta model. A modelling tool (15) modifies the meta model via an API (34) and a meta modeller (31). This allows dynamic re-configuration of the system.